Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg plus prednisolone for unexplained recurrent pregnancy loss after ART
2020-000256-35Phase 2Completed
- Sponsor
- Aalborg University Hospital
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in recurrent miscarriage (RPL) comparing Privigen + prednisolone with Placebo control (2 arms). Primary endpoints: Primary endpoint analysis subset 1, Primary endpoint analysis subset 2 and 2 more. Started Sep 2020; status: completed.
02
Drugs
polyvalent human immunoglobulinprednisolone
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on 2020-000256-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000256-35.